# Research: Exploring the Correlation Between Molecular Complexity and Degradation Rates in Pharmaceuticals

## 1. Executive Summary
This research aims to quantify the relationship between molecular complexity and pharmaceutical stability. By analyzing FDA-approved small molecules, we test the hypothesis that higher complexity (measured by TPSA, rotatable bonds, and graph indices) correlates with faster degradation rates. The study relies on public datasets and CPU-tractable statistical methods.

**Critical Finding**: No verified public dataset containing both FDA-approved structures and experimental degradation rates was found in the provided source list. The `Synthyra/FDA-Approved-Drugs` dataset contains structural properties but lacks experimental stability data. Consequently, the primary statistical analysis is contingent on the existence of a merged dataset. If the intersection of structural and degradation data is insufficient ($N < 30$), the project will report a "Data Insufficiency" finding rather than proceeding with invalid or synthetic data.

## 2. Dataset Strategy

### 2.1 Source Verification
The following datasets are used based on the **Verified datasets** block. No other URLs are cited.

| Dataset Purpose | Source Name | Verified URL | Loading Strategy |
|:--- |:--- |:--- |:--- |
| **FDA Structures** | Synthyra/FDA-Approved-Drugs | ` | `datasets.load_dataset` (parquet) |
| **FDA Structures (Alt)** | smdesai/fda-approved-drugs | ` | Fallback if primary lacks SMILES |
| **Degradation Data** | *None Verified* | N/A | **Critical Gap**: No verified source for experimental degradation half-lives exists in the provided list. |
| **SMILES Reference** | MKEChem/mke-novel-druglike-smiles | ` | Used for small-scale validation tests only |

**Note on Degradation Data**: The "Verified datasets" block lists NO source containing explicit degradation half-lives or rate constants for FDA-approved drugs.
* **Decision**: The implementation will first inspect the `Synthyra` dataset for any column resembling `degradation`, `half_life`, `stability`, or `t1/2`.
* **Contingency**: If no such column exists, the project will **NOT** generate synthetic data. It will generate a "Data Insufficiency Report" stating that the hypothesis cannot be tested with available public resources.
* **Impact**: This is a **blocking data gap** for a real-world scientific claim. The research will explicitly state: *"No verified public dataset containing both FDA-approved structures and experimental degradation rates was found in the source list. Analysis is limited to Data Insufficiency reporting."*

### 2.2 Variable Fit & Mismatch
- **Required Variables**: SMILES, Half-life (hours), pH, Temperature.
- **Potential Mismatch**: Most public chemical datasets (e.g., PubChem, DrugBank derivatives) contain structural data but **lack** experimental degradation rates.
- **Action**: The ingestion script will fail gracefully if the degradation column is missing, logging a "Critical Data Gap" error. The plan will not invent a dataset URL.

### 2.3 Formulation Context
- **Constraint**: Degradation rates are highly dependent on the physical form (solid vs. solution) and formulation matrix.
- **Action**: The analysis will only proceed if the dataset distinguishes between these forms. If the data is mixed without distinction, the analysis will be restricted to a descriptive summary only, as aggregating rates from different formulations introduces uncontrolled variance.

## 3. Statistical Methodology

### 3.1 Correlation Analysis
- **Method**: Pearson (linear) and Spearman (monotonic) correlation.
- **Threshold**: $|r| \ge 0.5$ for "moderate-to-strong" correlation.
- **Significance**: $p < 0.05$.
- **Correction**: Bonferroni correction applied for multiple comparisons (number of descriptors tested).
- **Data Subset**: Restricted to records with "Standard Conditions" (25°C, pH 7.4) only.

### 3.2 Regression Modeling
- **Model**: Multiple Linear Regression (MLR) and LASSO (L1 regularization).
- **Covariates**: pH and Temperature are **NOT** included as covariates for normalization because:
 1. Activation energy ($E_a$) is unavailable for the Arrhenius equation.
 2. pH dependence is non-Arrhenius.
 3. Including them without normalization would introduce confounding.
- **Strategy**: Records are stratified by condition. Only the "Standard" subset is used for regression.
- **Validation**: 5-fold Cross-Validation.
- **Metric**: Cross-validated $R^2$.

### 3.3 Assumptions & Limitations
- **Observational Nature**: No randomization; findings are associational.
- **Power**: Sample size limited by the intersection of "FDA-approved" and "has degradation data". If $N < 30$, statistical power is low; the project will report "Data Insufficiency".
- **Collinearity**: Complexity metrics (e.g., MW and Rotatable Bonds) may be correlated. VIF (Variance Inflation Factor) will be checked. If VIF > 5, multicollinearity is reported, and LASSO is preferred.
- **Data Gap**: The primary limitation is the likely absence of experimental degradation data in public structural datasets.

## 4. Compute Feasibility
- **Memory**: Data processed in chunks. RDKit calculations vectorized.
- **Time**: Target < 6 hours.
- **Hardware**: CPU-only. No CUDA.

## 5. Decision Log
- **Dataset Selection**: `Synthyra/FDA-Approved-Drugs` selected as primary source due to verified URL.
- **Degradation Gap**: No verified degradation source found. Strategy: Attempt to parse available columns; if missing, report "Data Insufficiency". **No synthetic data**.
- **Normalization**: Arrhenius equation **NOT** applied due to missing $E_a$ and non-Arrhenius pH dependence. Records are stratified by condition.
- **Formulation**: Analysis restricted to single-formulation subsets if possible; otherwise descriptive only.